ClinicalTrials.gg
CompletedNCT03680417Updated Sep 12, 2019

Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

A Phase 4 interventional study of Measles-Rubella (MR) Vaccine in Safety Issues and Immunogenicity, sponsored by PT Bio Farma. Completed at 1 site in Indonesia. Open to participants aged 9 Months to 47 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-12.

Sponsored by PT Bio Farma · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2017, registered Sep 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
590
Allocation
Randomized
Ages
9 Months to 47 Months
Sex
All
01

Study summary

to assess safety and immunogenicity of measles-rubella (MR) routine immunization in Indonesian Children and Infants

Read the detailed description
  • to asses serious immediate systemic events,
  • to assess local and systemic reaction after Measles-Rubella (MR) vaccine in infants and children,
  • to evaluate protectivity and antibody response to measles and rubella after 1 dose of MR vaccine
02

Conditions studied

  • Safety Issues
  • Immunogenicity

Keywords

  • Measles-Rubella
  • Vaccine
  • Safety
  • Immunogenicity
  • Reactogenicity
  • Protectivity
03

In context

Lead sponsor

PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Months to 47 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy infants (9-12 months) or children (18-47 months)
  • Will receive MR routine immunization.
  • Parents have been informed properly regarding the study and signed the form.
  • Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial.

Exclusion criteria

Exclusion Criteria:

  • MR vaccine given simultaneously with other vaccination, except Pentabio (DTP/HB/Hib)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
590 participants (actual)

Study arms

  • Active comparator
    Safety Study (Measles-Rubella vaccine)

    open labeled, prospective intervention study, only assess the safety outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. This study group only assessed for safety profile of the Measles-Rubella vaccine.

    Biological: Measles-Rubella (MR) Vaccine

  • Active comparator
    Sub Study (Measles-Rubella vaccine)

    open labeled, prospective intervention study, assess the safety and immunogenicity outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. For Sub study, pre- and post immunization sera will be obtained from 200 infants and/or children. Safety assessment also evaluated for 28 days after immunization.

    Biological: Measles-Rubella (MR) Vaccine

Interventions

  • BiologicalMeasles-Rubella (MR) Vaccine

    Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.

06

What researchers measure

Primary outcomes

  1. Number of Immediate systemic events

    Number of subjects with at least one serious immediate systemic events within 30 minutes after vaccination

    Time frame: 30 minutes

  2. Percentage of immediate systemic events

    Percentage of subjects with at least one serious immediate systemic events within 30 minutes after vaccination

    Time frame: 30 minutes

Secondary outcomes

  1. Local reaction

    Number of subjects with at least one local reaction occurring within 72 h after vaccination.

    Time frame: 72 hours

  2. Systemic reaction

    Number of subjects with at least one systemic event occurring within 72 h after vaccination.

    Time frame: 72 hours

  3. Delayed Local reaction

    Number of subjects with at least one local reaction occurring between day 4-14 after vaccination.

    Time frame: 11 days

  4. Delayed systemic event

    Number of subjects with at least one systemic event occurring between day 4-14 after vaccination.

    Time frame: 11 days

  5. Late Local reaction

    -Number of subjects with at least one systemic event occurring between day 15 to 28 following vaccination.

    Time frame: 14 days

  6. Late Safety (Systemic event)

    Number of subjects with at least one systemic event occurring between day 15 to 28 following vaccination.

    Time frame: 14 days

  7. Safety (serious adverse event)

    - Number of serious adverse event occuring from inclusion until 28 days after immunization

    Time frame: 28 days

  8. Immunogenicity for Measles (subject with anti measles titer ≥ 8 (1/dil))

    - Percentage of subjects with anti measles titer ≥ 8 (1/dil), 28 days after one dose of MR vaccine in Infants \& Children.

    Time frame: 28 days

  9. Immunogenicity for Measles (Geometric Mean Titer)

    - Geometric Mean Titer of measles antibody

    Time frame: 28 days

  10. Immunogenicity for Measles (increasing measles antibody titer ≥ 4 times)

    - Percentage of infants with increasing measles antibody titer ≥ 4 times

    Time frame: 28 days

  11. Immunogenicity for Measles (seroconversion from seronegative to seropositive)

    - Percentage of infants with transition of seronegative to seropositive.

    Time frame: 28 days

  12. Immunogenicity for Rubella (Subjects with anti rubella titer ≥11 IU/ml)

    - Percentage of subjects with anti rubella titer ≥11 IU/ml, 28 days after one dose of MR vaccine in Infants \& Children.

    Time frame: 28 days

  13. Immunogenicity for Rubella (Geometric Mean Titer)

    - Geometric Mean Titer of Rubella antibody.

    Time frame: 28 days

  14. Immunogenicity for Rubella (increasing rubella antibody titer ≥ 4 times)

    - Percentage of infants with increasing rubella antibody titer ≥ 4 times

    Time frame: 28 days

  15. Immunogenicity for Rubella (seroconversion from seronegative to seropositive)

    - Percentage of infants with transition of seronegative to seropositive.

    Time frame: 28 days

07

Study locations

1 site
  • Child Health Dept. Dr. Soetomo Hospital, School of Medicine Airlangga Univ.
    Surabaya, East Java 60131, Indonesia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Feb 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2018
First posted
Sep 21, 2018
StartActual
Nov 16, 2017
Primary completionActual
Feb 26, 2018
CompletionActual
Aug 1, 2018
Last update
Sep 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03680417
Lead sponsor
PT Bio Farma
Responsible party
Sponsor
First posted
Sep 21, 2018
Start date
Nov 16, 2017
Primary completion
Feb 26, 2018
Completion
Aug 1, 2018
Last update
Sep 12, 2019

Study contacts

Dominicus Husada, Dr
principal investigator · Child Health Dept. Dr. Soetomo Hospital/School of Medicine, Airlangga Univ.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion